Clinical Drug Investigation

, Volume 33, Issue 9, pp 685–688

Infant Health and Neurodevelopmental Outcomes Following Prenatal Exposure to Duloxetine

Authors

  • Cesario Bellantuono
    • Psychiatric Unit and DEGRA Centre, United Hospital of Ancona and Academic Department of Experimental and Clinical MedicinePolytechnic University of Marche
  • Alessandra Marini
    • Psychiatric Unit and DEGRA Centre, United Hospital of Ancona and Academic Department of Experimental and Clinical MedicinePolytechnic University of Marche
    • Psychiatric Unit and DEGRA Centre, United Hospital of Ancona and Academic Department of Experimental and Clinical MedicinePolytechnic University of Marche
Case Report

DOI: 10.1007/s40261-013-0112-y

Cite this article as:
Bellantuono, C., Marini, A. & Lucarelli, C. Clin Drug Investig (2013) 33: 685. doi:10.1007/s40261-013-0112-y

Abstract

Maternal psychiatric disorders can have negative consequences on the fetus and newborn. Thus, the risks of untreated mental disorders in pregnancy should be balanced against the potential risks of a psychopharmacological treatment. The aim of the present report is to provide information on the infant safety of duloxetine exposure, an antidepressant drug belonging to the serotonin–norepinephrine reuptake inhibitors, during pregnancy. Despite duloxetine being routinely prescribed as a treatment for major depression and anxiety disorders, there is a paucity of literature evaluating both the short- and long-term effects of duloxetine exposure in utero. This paper provides data on infant health and neurodevelopmental outcomes, up to 9 months of age, in a newborn exposed to duloxetine throughout pregnancy. Although the present report suggests that duloxetine was not associated with major malformations or neurobehavioural problems, the drug should be used with caution until further information is available on its safety profile in pregnancy.

Copyright information

© Springer International Publishing Switzerland 2013